David J. Valacer

Dr. Valacer brought many years of clinical experience to his new position at Regor. Before joining Regor, Dr. Valacer was a Vice President of clinical development at Array Biopharma, Inc where he oversaw Phase I and II clinical trials in non-small cell lung colorectal, ovarian and pancreatic cancers. Prior to joining Array, he served as Chief Medical Officer at Molecular Templates where he oversaw transition into the clinic and development of MT-3724, a recombinant fusion CD20 binding variable fragment fused to a Shiga-like toxin-I A1 subunit. Prior to entering the pharmaceutical industry, Dr. Valacer served as a Professor of Clinical Immunology at the New York Hospital-Weill Cornell Medical College for 10 years. Following his first position in clinical drug development at Hoffman-LaRoche, Inc. he progressed through positions of increasing responsibility at Genentech and Boehringer Ingelheim, Inc. He moved into the small biotech space in 2009 where he has since managed development programs across oncology, diabetes and autoimmune diseases. Dr. Valacer graduated Magna Cum Laude with a degree in Chemistry from the College of the Holy Cross and received his Doctor of Medicine degree from the University of Vermont. Following his internship and residency at Columbia-Presbyterian Medical Center he completed a Fellowship at the University of California San Francisco.